- $63.42m
- $31.87m
- $30.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.13 | ||
| Price to Tang. Book | 2.2 | ||
| Price to Free Cashflow | 21.97 | ||
| Price to Sales | 2.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.64% | ||
| Return on Equity | -9.61% | ||
| Operating Margin | -12.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.88 | 28.01 | 21.22 | 20.15 | 30.26 | 32.17 | n/a | 123.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Forian Inc. is a healthtech company. It is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers within the healthcare and life sciences and financial services industries. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its solutions include CHRONOS, Chartis, real-world evidence (RWE) and Kyber Data Science. CHRONOS combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model. It also provides researchers access to healthcare payers, providers, and clinical data with non-traditional healthcare sources, such as social determinants of health (SDoH) data, to uncover novel insights.
Directors
- Max Wygod CHM (33)
- Daniel Barton CEO (56)
- Michael Vesey CFO (61)
- Edward Spaniel EVP (51)
- Adam Dublin OTH (55)
- Martin Wygod DRC (78)
- Mark Adler IND (61)
- Ian Banwell IND (57)
- Jennifer Hajj IND (37)
- Shahir Kassam-Adams IND (61)
- Stanley Trotman IND (77)
- Alyssa Varadhan IND (40)
- Kristiina Vuori IND (53)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- January 8th, 2026
- Public Since
- March 3rd, 2021
- No. of Shareholders
- 252
- No. of Employees
- 50
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 29,499,634
- Address
- 41 University Drive, Suite 400, NEWTOWN, 18940
- Web
- https://forian.com/
- Phone
- +1 2672256263
- Auditors
- Marcum LLP
Upcoming Events for FORA
Forian Inc Annual Shareholders Meeting
Similar to FORA
20/20 Biolabs
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Forian. share price?
As of Today at 20:41 UTC, shares in Forian. are trading at $2.15. This share price information is delayed by 15 minutes.
How has the Forian. share price performed this year?
Shares in Forian. last closed at $2.15 and the price had moved by +8.09% over the past 365 days. In terms of relative price strength the Forian. share price has underperformed the S&P500 Index by -17.31% over the past year.
What are the analyst and broker recommendations for Forian.?
The overall consensus recommendation for Forian. is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Forian. dividend yield?
Forian. does not currently pay a dividend.
Does Forian. pay a dividend?
Forian. does not currently pay a dividend.
When does Forian. next pay dividends?
Forian. does not currently pay a dividend.
How do I buy Forian. shares?
To buy shares in Forian. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Forian.?
As of the previous close price of $2.15, shares in Forian. had a market capitalisation of $63.42m.
Where are Forian. shares listed?
Here are the trading details for Forian.:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FORA
What kind of share is Forian.?
Based on an overall assessment of its quality, value and momentum Forian. is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Forian. share price forecast for 2026?
The analyst consensus target price for shares in Forian. is $2.10. That is 2.33% below the last closing price of $2.15.
Analysts covering Forian. currently have a consensus Earnings Per Share (EPS) forecast of $0.09 for the next financial year.
Find out moreWhat is the trend in the Forian. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Forian.. Over the past six months, its share price has underperformed the S&P500 Index by -7.66%.
As of the last closing price of $2.15, shares in Forian. were trading +1.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Forian. PE Ratio?
The Forian. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Forian.?
Forian.'s management team is headed by:
- Max Wygod - CHM
- Daniel Barton - CEO
- Michael Vesey - CFO
- Edward Spaniel - EVP
- Adam Dublin - OTH
- Martin Wygod - DRC
- Mark Adler - IND
- Ian Banwell - IND
- Jennifer Hajj - IND
- Shahir Kassam-Adams - IND
- Stanley Trotman - IND
- Alyssa Varadhan - IND
- Kristiina Vuori - IND